Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/ASO.2004.12.935
Annals of Surgical Oncology 11:186S-191 (2004)
© 2004 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reintgen, D. S.
Right arrow Articles by Shivers, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reintgen, D. S.
Right arrow Articles by Shivers, S.

SUPPLEMENT

The Staging of Malignant Melanoma and the Florida Melanoma Trial

Douglas S. Reintgen, MD, James W. Jakub, MD, Solange Pendas, MD, Gray Swor, MD, Rosemary Giuliano, ARNP, MSN and Steve Shivers, PhD

From the Cutaneous Oncology Program, Lakeland Regional Cancer Center, Lakeland, Florida.

Correspondence: Address correspondence and reprint requests to: Douglas Reintgen, MD, Lakeland Regional Cancer Center, 3525 Lakeland Hills Blvd., P. O. Box 91057, Lakeland, FL 33804–1057; Fax: 863-904-1802; E-mail: Doug.Reintgen{at}lrmc.com

ABSTRACT

Lymphatic mapping and sentinel lymph node (SLN) biopsy have changed the standard of care for patients with malignant melanoma, by providing a less morbid procedure to obtain the nodal staging information that is critical for therapeutic decisions. Detailed examination of the SLN identifies patients who have an increased risk for recurrence and death. Patients whose melanoma is upstaged with very sensitive assays based on reverse transcriptase polymerase chain reaction technology are better targeted for clinical trials or surgical or adjuvant therapies. In the future, melanoma may be "ultrastaged" by examining the SLNs, peripheral blood, and bone marrow. This may improve identification of patients who are surgically cured of their disease and therefore can be spared the side effects of more radical surgery or the toxicities of adjuvant therapy. The lymphatic mapping procedure is the most accurate way to determine the tumor status of the regional lymph nodes.

Key Words: Lymphatic mapping • Malignant melanoma • Sentinel lymph node biopsy • Staging




This article has been cited by other articles:


Home page
 Arch SurgHome page
B. E. Wright, R. P. Scheri, X. Ye, M. B. Faries, R. R. Turner, R. Essner, and D. L. Morton
Importance of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma
Arch Surg, September 1, 2008; 143(9): 892 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. Govindarajan, D. M. Ghazarian, D. R. McCready, and W. L. Leong
Histological Features of Melanoma Sentinel Lymph Node Metastases Associated with Status of the Completion Lymphadenectomy and Rate of Subsequent Relapse
Ann. Surg. Oncol., February 1, 2007; 14(2): 906 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
D. R. Berk, D. L. Johnson, A. Uzieblo, M. Kiernan, and S. M. Swetter
Sentinel Lymph Node Biopsy for Cutaneous Melanoma: The Stanford Experience, 1997-2004
Arch Dermatol, August 1, 2005; 141(8): 1016 - 1022.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society of Surgical Oncology.